CGEN Stock — Compugen Ltd.: Cash, EV, Pipeline

What they do

We were incorporated on February 10, 1993, as an Israeli corporation and operate under the Companies Law. Our principal offices are located at 26 Harokmim Street, Holon 5885849, Israel, and our telephone number is +972-3-765-8585. Our web address is www.cgen.com .

Source: 20-F FY2025 via SEC EDGAR

Share price

$1.96

Market cap

$185.4M

Cash

$145.6M

Enterprise value

$39.8M

Balance sheet

Cash	$145.6M
Debt	$0.0M
Net cash	$145.6M
Enterprise value	$39.8M
Basic shares	94.6M shares
Fully diluted shares	103.7M shares
Fully diluted market cap	$203.3M
Cash per share	$1.54
Quarterly burn	+$25.1M generated

Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.

Share structure

Common

94.6M

Pre-funded warrants

—

Options

8.6M

RSUs

0.6M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

103.7M

Cap table as of 2025-12-31.

Price history

Loading CGEN daily closes…

Loading price history…

Next catalyst

COM701 · Est. Feb 14, 2027 · quarter midpoint · guided in 8 wks

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Feb 14, 2027 in 8 wks quarter midpoint	COM701 MAIA-ovarian adaptive platform trial interim analysis, median progression-free survival data · NCT06888921	Not disclosed	MAIA-ovarian adaptive platform trial , median progression-free survival	Q1 2027
Apr 12 - May 24 in 5 mo	COM701	Phase 2	Ovarian Cancer; Ovarian Cancer Recurrent	—
Jan 3 - Feb 14 in 14 mo	COM503	Phase 1	Neoplasm; Cancer, Malignant Tumors	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

rilvegostomig

Phase 3 · Active Modality: bispecific antibody

Target PD-1 / TIGIT

Partnerships AstraZeneca (exclusive license, as amended December 16, 2025, to use Compugen's monospecific anti-TIGIT antibodies including COM902 for development of bi-specific and multi-specific antibody products; AstraZeneca developed rilvegostomig and is evaluating it)

Indications

Not disclosed (Phase 3)

Status note PD-1/TIGIT bi-specific antibody with a TIGIT component derived from COM902. Being evaluated by AstraZeneca in multiple Phase 3, Phase 2 and Phase 1 clinical trials. Filing notes recent failures in the TIGIT field (including discontinuation of the Phase 3 STAR-221 domvanalimab-based combination in upper GI cancers in December 2025 due to futility).

COM701

Phase 1 · Active Modality: monoclonal antibody

Target PVRIG

Indications

Solid tumors (Phase 1)
Relapsed platinum-sensitive ovarian cancer (maintenance) (Stage not disclosed)

Status note Anti-PVRIG antibody. Phase 1 trials conducted as monotherapy, in combination with nivolumab, and in triplet combinations. Currently conducting the MAIA-ovarian platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum-sensitive ovarian cancer.

COM902

Phase 1 · Active Modality: monoclonal antibody

Target TIGIT

Indications

Solid tumors (Phase 1)

Status note Therapeutic anti-TIGIT antibody evaluated in a Phase 1 dose escalation monotherapy trial. Based on negative data in the TIGIT field, the company currently believes COM902 has limited near-term value potential and does not plan to initiate new clinical trials with it; the decision may be revisited pending further TIGIT data from other companies.

GS-0321

Phase 1 · Active Modality: monoclonal antibody

Aliases COM503

Target IL-18 binding protein (IL-18 pathway)

Partnerships Gilead (exclusive license to the preclinical anti-IL-18 binding protein antibody program, December 2023; Compugen is responsible for conducting a Phase 1 clinical trial of GS-0321 including regulatory matters)

Indications

Not disclosed (Phase 1)

Status note Antibody targeting the IL-18 pathway. Licensed to Gilead; currently being evaluated in a Phase 1 clinical trial that Compugen sponsors and conducts. Compugen is responsible only for Phase 1 clinical development.

Per-asset detail extracted from the 20-F filed 2026-03-02. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	COM701
Lead indication	Ovarian Cancer
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06888921	Phase 2	Recruiting	Sponsor	CGEN	—	Ovarian Cancer; Ovarian Cancer Recurrent	Q1 2027 Est. Feb 14, 2027 · quarter midpoint
NCT06759649	Phase 1	Recruiting	Sponsor	CGEN	GILD	Neoplasm; Cancer, Malignant Tumors	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Compugen Ltd on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
DAFNA Capital	168,232	-89,551	0.07%	2026-08-14
Stonepine Capital	31,387	-72,913	0.05%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CGEN — Compugen Ltd. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

CGEN — Compugen Ltd.